EUR 53.2
(0.95%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 77.69 Million EUR | 82.83% |
2022 | 42.49 Million EUR | 16.07% |
2021 | 36.61 Million EUR | 6.97% |
2020 | 34.22 Million EUR | 3.23% |
2019 | 33.15 Million EUR | -22.88% |
2018 | 42.99 Million EUR | 48.24% |
2017 | 29 Million EUR | 48.48% |
2016 | 19.53 Million EUR | 15.41% |
2015 | 16.92 Million EUR | 34.49% |
2014 | 12.58 Million EUR | 4456.93% |
2013 | 276.17 Thousand EUR | 99.5% |
2012 | 138.43 Thousand EUR | 0.0% |
2011 | - EUR | -100.0% |
2010 | 49.25 Thousand EUR | 146.26% |
2009 | 20 Thousand EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 26.89 Million EUR | 0.0% |
2023 Q4 | 33.9 Million EUR | 0.0% |
2023 FY | 77.69 Million EUR | 82.83% |
2023 Q2 | 43.78 Million EUR | 0.0% |
2022 Q2 | 17.64 Million EUR | 0.0% |
2022 FY | 42.49 Million EUR | 16.07% |
2022 Q4 | 24.85 Million EUR | 0.0% |
2021 Q2 | 20.3 Million EUR | 0.0% |
2021 FY | 36.61 Million EUR | 6.97% |
2021 Q4 | 16.65 Million EUR | 0.0% |
2020 Q4 | 17.71 Million EUR | 0.0% |
2020 Q2 | 16.5 Million EUR | 0.0% |
2020 FY | 34.22 Million EUR | 3.23% |
2019 FY | 33.15 Million EUR | -22.88% |
2019 Q4 | 15.92 Million EUR | 0.0% |
2019 Q2 | 17.22 Million EUR | 0.0% |
2018 FY | 42.99 Million EUR | 48.24% |
2018 Q4 | 18.4 Million EUR | 0.0% |
2018 Q2 | 24.59 Million EUR | 0.0% |
2017 Q4 | 20.9 Million EUR | 0.0% |
2017 FY | 29 Million EUR | 48.48% |
2017 Q2 | 8.09 Million EUR | 0.0% |
2016 Q2 | 8.76 Million EUR | 0.0% |
2016 Q4 | 10.77 Million EUR | 0.0% |
2016 FY | 19.53 Million EUR | 15.41% |
2015 FY | 16.92 Million EUR | 34.49% |
2015 Q4 | 7.1 Million EUR | 0.0% |
2015 Q2 | 9.81 Million EUR | 0.0% |
2014 Q4 | 11.96 Million EUR | 0.0% |
2014 FY | 12.58 Million EUR | 4456.93% |
2014 Q2 | 622.83 Thousand EUR | 0.0% |
2013 Q3 | 69.04 Thousand EUR | 0.0% |
2013 Q1 | 69.04 Thousand EUR | 0.0% |
2013 Q2 | 69.04 Thousand EUR | 0.0% |
2013 Q4 | 3.14 Million EUR | 4456.95% |
2013 FY | 276.17 Thousand EUR | 99.5% |
2012 Q4 | 69.04 Thousand EUR | 99.51% |
2012 Q3 | 34.6 Thousand EUR | 0.0% |
2012 Q2 | 34.6 Thousand EUR | 0.0% |
2012 Q1 | 34.6 Thousand EUR | 0.0% |
2012 FY | 138.43 Thousand EUR | 0.0% |
2011 Q4 | 34.6 Thousand EUR | 0.0% |
2011 Q3 | - EUR | 0.0% |
2011 Q1 | - EUR | 0.0% |
2011 Q2 | - EUR | 0.0% |
2011 FY | - EUR | -100.0% |
2010 FY | 49.25 Thousand EUR | 146.26% |
2010 Q4 | - EUR | -100.0% |
2010 Q3 | 12.31 Thousand EUR | 0.0% |
2010 Q2 | 12.31 Thousand EUR | 0.0% |
2010 Q1 | 12.31 Thousand EUR | 0.0% |
2009 Q3 | 5000.00 EUR | 0.0% |
2009 Q1 | 5000.00 EUR | 0.0% |
2009 Q2 | 5000.00 EUR | 0.0% |
2009 FY | 20 Thousand EUR | 0.0% |
2009 Q4 | 12.31 Thousand EUR | 146.26% |
2008 Q4 | 5000.00 EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Boiron SA | 493.24 Million EUR | 84.248% |
Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 90.633% |
Vetoquinol SA | 529.27 Million EUR | 85.32% |
Valneva SE | 153.71 Million EUR | 49.454% |
AB Science S.A. | 970 Thousand EUR | -7909.897% |
Nanobiotix S.A. | 30.05 Million EUR | -158.487% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -5759.427% |
Vivoryon Therapeutics N.V. | -3.62 Million EUR | 2246.298% |
BioSenic S.A. | 543 Thousand EUR | -14208.656% |
ABIVAX Société Anonyme | 4.62 Million EUR | -1581.368% |